Amgen Inc Investor Call Transcript
Hello, and welcome. My name is Alex, and I will be your conference facilitator today for the Amgen analyst and investor conference call from the World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease Conference. (Operator Instructions) I would now like to introduce David Reese, Executive Vice President of Research and Development. Dr. Reese, you may now begin.
Thanks, Alex, and good morning, everyone. Thanks for joining us for an update on the AMG 133 program in obesity and allied disorders. These are review of data just presented at the World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease.
Next slide, please. Here's our standard safe harbor disclaimer. I did note that these slides are up on our website now for those who wish to follow along.
Next slide, please. In terms of today's agenda, I will provide a brief introduction to our strategy in obesity and allied disorders following which Narimon, the Head of our cardiometabolic group in
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |